NCT01266967已完成2 期
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 172
- 试验地点
- 1
- 主要终点
- Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator
研究概览
简要总结
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cohort A:
- •No prior local therapy for brain metastases.
- •Subjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 3 weeks prior to first dose of study treatment.
- •No prophylactic or preventive anti-epileptic therapy. Exception: anti-epileptic therapy indicated in order to prevent neurologic symptoms caused by a pre-existing condition and not related to brain metastasis is allowed.
- •Cohort B:
- •Subjects must have received at least one local therapy for brain metastases including but not restricted to brain surgery, Whole Brain Radiotherapy or Stereotactic Radiosurgery (e.g. gamma knife, linear-accelerated-based radiosurgery, charged particles, and CyberKnife). Multiple local therapies or combinations of local therapies are allowed. For subjects receiving local therapy to all brain lesions (including WBRT), progression of pre-existing lesions based on RECIST 1.1 (> 20% increase in longest diameter on baseline scan) or new measurable lesions are required. For subjects receiving local therapy for some but not all lesions, disease progression based on RECIST 1.1 is not required as long as there are remaining brain lesions that are measurable and not previously treated.
- •Subjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 2 weeks prior to first dose of study treatment.
- •Prophylactic or preventive anti-epileptic therapy is allowed.
- •Must sign written informed consent.
- •Must be at least 18 years of age.
- •Histologically confirmed metastatic melanoma (Stage IV), carrying BRAF V600E- or V600K-mutation.
- •Up to two previous treatment regimens for extracranial metastatic melanoma including chemo-, cytokine-, immuno-, biological- and vaccine-therapy.
- •At least one measurable intracranial target lesion for which all of the following criteria have to be met:
- •previously untreated or progressive according to RECIST 1.1 (greater than or equal to 20% increase in longest diameter on baseline scan) after previous local therapy
- •immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy
- •largest diameter of greater than or equal to 0.5cm but less than or equal to 4 cm as determined by contrast-enhanced MRI
- •for target lesions (for definition see Section 6.1.1) with diameter of greater than 0.5 cm but less than or equal to 1 cm documented measurement by a neuroradiologist is required.
- •for all lesions with diameter of greater than or equal to 3 cm but less than or equal to 4 cm documented measurement by a neuroradiologist is required.
- •Time interval between last day of previous anti-tumour systemic treatment and first dose of GSK2118436:
- •14 days elapsed from last treatment with surgery, SRS or gamma knife
- •28 days elapsed from last treatment with WBRT
- •Greater than or equal to 28 days or five half-lives (whichever is longer) have elapsed from last dose of approved or investigational chemo-, cytokine-, immune-, biological-, or vaccine-therapy.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Adequate organ function.
- •Women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.
- •Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study treatment.
排除标准
- •Neurological symptoms related to brain metastasis.
- •Previous treatment with a BRAF or MEK inhibitor.
- •Current or expected use of a prohibited medication during treatment with GSK
- •Presence of leptomeningeal disease or primary dural metastases.
- •Known allergies against contrast agents required for magnetic resonance imaging (MRI) of intracranial lesions.
- •Current use of therapeutic warfarin. NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permitted.
- •Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.
- •Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
- •A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
- •Acute infection requiring intravenous antibiotics
- •History of another malignancy. Exception: (a) Subjects who have been disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer requiring no or only anti-hormonal therapy with histologically confirmed tumour lesions that can be clearly differentiated from melanoma target and non-target lesions are eligible.
- •Certain cardiac abnormalities.
研究组 & 干预措施
Single Arm
Experimental
Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
干预措施: GSK2118436 (Drug)
结局指标
主要结局
Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator
时间窗: From the time of the Baseline assessment until disease progression or end of study treatment (average of 18.3 weeks)
OIR is defined as the number of participants whose intracranial response was a confirmed complete response (CR) or partial response (PR) assessed by investigators using modified Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. CR is defined as disappearance of all lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters (e.g., percent change from Baseline). For the primary analysis, OIR was measured when all participants in both treatment arms had two post-Baseline disease assessments. Participants who had an intracranial response of not evaluable or a missing response were treated as non-responders. Confirmation assessments were to be performed no less than 4 weeks after the criteria for response were initially met and may have been performed at the next protocol scheduled assessment.
次要结局
- Number of Participants With V600E Mutation-positive Melanoma With a Best Overall Response (OR) of CR or PR, as Assessed by the Investigator(From the time of the Baseline assessment until disease progression or end of study treatment (average of 24 weeks))
- Duration of Overall Response for the Subset of V600E Mutation-positive Participants(Time from the first documented evidence of CR or PR until the time of the first documented disease progression or death due to any cause (average of 28 weeks))
- Duration of Overall Response for the Subset of V600K Mutation-positive Participants(Time from the first documented evidence of CR or PR until the time of the first documented disease progression or death due to any cause (average of 31 weeks))
- Number of Participants With V600K Mutation-positive Melanoma With a Best Overall Response (OR) of CR or PR, as Assessed by the Investigator(From the time of the Baseline assessment until disease progression or end of study treatment (average of 17 weeks))
- Number of Participants With V600K Mutation-positive Melanoma With OIR, as Assessed by the Investigator(From the time of the Baseline assessment until disease progression or end of study treatment (average of 16 weeks))
- Duration of Intracranial Response for the Subset of V600E Mutation-positive Participants(Time from the first documented evidence of intracranial CR or PR until the time of the first documented intracranial disease progression or death due to any cause (average of 27 weeks))
- Duration of Intracranial Response for the Subset of V600K Mutation-positive Participants(Time from the first documented evidence of intracranial CR or PR until the time of the first documented intracranial disease progression or death due to any cause (average of 31 weeks))
- Progression-free Survival in V600E Mutation-positive Participants(Time from the first dose of study medication to the earliest of death or progression (average of 23 weeks))
- Progression-free Survival in V600K Mutation-positive Participants(Time from the first dose of study medication to the earliest of death or progression (average of 17 weeks))
- Overall Survival of V600E Mutation-positive Participants(Time from the first dose of study medication until death due to any cause (average of 35 weeks))
- Overall Survival in V600K Mutation-positive Participants(Time from the first dose of study medication until death due to any cause (average of 26 weeks))
- Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)(From Screening until the conclusion of the study (up to 103 weeks))
- Number of Participants With a Worst-case on Therapy Change to Grade 3 and Grade 4, or With Any Grade Increase (AGI), From Baseline Grade for Clinical Chemistry Parameters(From Screening until the conclusion of the study (up to 103 weeks))
- Number of Participants With the Indicated Hepatobiliary Laboratory Abnormalities(From Screening until the conclusion of the study (up to 103 weeks))
- Number of Participants With a Worst-case on Therapy Change to Grade 3 and Grade 4, or With Any Grade Increase (AGI), From Baseline Grade for Hematology Parameters(From Screening until the conclusion of the study (up to 103 weeks))
- Mean Blood Pressure at Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, and 36(Baseline; Weeks 4, 8, 12, 16, 20, 24, 28, 32, and 36)
- Number of Participants With a Worst-case On-therapy Increase From Baseline in Bazett's QTc Reading in the 12-lead Electrocardiogram (ECG)(Baseline; Weeks 4, 12, 20, 28, 40, 52, and 64)
- Number of Participants With Abnormal Echocardiograms (ECHO) at Weeks 4 and 12(Weeks (W) 4 and 12)
- Median Concentrations of GSK2118436 and Its Metabolites Including GSK2285403, GSK2298683, and GSK2167542(Week 4 (pre-dose and 1-3 hours post-dose) and Weeks 8, 16, 24, and 32 (either pre-dose in the morning or in the afternoon at 4-8 hours post-dose))
- Composite of Pharmacokinetic Parameters of GSK2118436 in a Subset of Participants Receiving Dexamethasone(Day 15)
- Number of Response Genetics Incorporated (RGI) Investigational Use Only (IUO) Assay Mutation Positive Participants and THxID BRAF Assay Mutation Positive Participants With the Indicated Best Intracranial Response(Screening)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With SchizophreniaSchizophreniaNCT02411695Otsuka Pharmaceutical Development & Commercialization, Inc.43
Unknown
1 期
A Phase I Study of BR790 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04891653Jiangxi Qingfeng Pharmaceutical Co. Ltd.48
撤回
1 期
BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)Lupus Erythematosus, SystemicNCT03771885Boehringer Ingelheim
已完成
3 期
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor OveractivityNeurogenic Detrusor OveractivityNCT02751931Astellas Pharma Europe B.V.91
招募中
1 期
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT04953897Taiho Oncology, Inc.18